61.   The bill faces a tough battle because of the strength of the pharmaceutical lobby and its generous contributions to lawmakers.

62.   The bill faces a tougher battle in the Senate, and would almost certainly be vetoed by President Bill Clinton.

63.   The bill faces one more House vote and would not be retroactive.

64.   The bill still faces a long, difficult journey.

65.   The bill still faces tough going in the full House.

66.   The bill will also face numerous amendments from lawmakers on the left and right, who may envision it as a vehicle for other priorities in the energy field.

67.   The bills still face opposition.

68.   The bill faces a final House vote, probably Saturday, that would send it to the Senate, where a similar measure has stalled in committee.

69.   The bill faces an even tougher fight in the House, with a handful of Republicans saying they would introduce separate legislation.